Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017200156 - NANOPARTICLES FOR CHEMOTHERAPY FOR ANOIKIS-RESISTANT CANCER CELLS

Publication Number WO/2017/200156
Publication Date 23.11.2017
International Application No. PCT/KR2016/011348
International Filing Date 11.10.2016
IPC
A61K 31/704 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
704attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 47/42 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
CPC
A61K 31/704
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
704attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
A61K 47/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Applicants
  • 서강대학교 산학협력단 SOGANG UNIVERSITY RESEARCH FOUNDATION [KR]/[KR]
Inventors
  • 김현철 KIM, Hyun Cheol
  • 이호현 LEE, Ho Hyun
Agents
  • 김현진 KIM, Hyun Jin
Priority Data
10-2016-006215520.05.2016KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) NANOPARTICLES FOR CHEMOTHERAPY FOR ANOIKIS-RESISTANT CANCER CELLS
(FR) NANOPARTICULES POUR CHIMIOTHÉRAPIE POUR CELLULES CANCÉREUSES RÉSISTANTES À L'ANOÏKOSE
(KO) 아노이키스 내성 암세포의 화학요법을 위한 나노입자
Abstract
(EN)
The present invention relates to albumin nanoparticles for chemotherapy for anoikis-resistant cancer cells, and more specifically, to albumin nanoparticles for chemotherapy for anoikis-resistant cancer cells, the albumin nanoparticles comprising: albumin nanoparticles having a drug impregnated therein; and a CEACAM6 antibody bonding with the albumin nanoparticles, wherein the albumin nanoparticles are formed by means of disulfide bonds formed among albumin molecules, and the CEACAM6 antibody forms an amide bond with an amine group on the surface of the albumin nanoparticles, and thus the CEACAM6 antibody targets anoikis-resistant cancer cells, and the albumin nanoparticles ingested by the cancer cells discharge the drug by having the disulfide bonds thereof broken due to glutathione existing in the cytosol.
(FR)
La présente invention concerne des nanoparticules d'albumine pour une chimiothérapie pour des cellules cancéreuses résistantes à l'anoïkose, et plus spécifiquement, des nanoparticules d'albumine pour une chimiothérapie pour des cellules cancéreuses résistantes à l'anoïkose, les nanoparticules d'albumine comprenant : des nanoparticules d'albumine dans lesquelles un médicament est imprégné ; et un anticorps CEACAM6 lié aux nanoparticules d'albumine, les nanoparticules d'albumine étant formées au moyen de liaisons disulfure formées entre les molécules d'albumine, et l'anticorps CEACAM6 forme une liaison amide avec un groupe amine sur la surface des nanoparticules d'albumine et, par conséquent, l'anticorps CEACAM6 cible des cellules cancéreuses résistantes à l'anoïkose, et les nanoparticules d'albumine ingérées par les cellules cancéreuses libèrent le médicament lorsque leurs liaisons disulfure se rompent sous l’effet du glutathion présent dans le cytosol.
(KO)
본 발명은 아노이키스 내성 암세포의 화학요법을 위한 알부민 나노입자에 대한 것으로, 더욱 상세하게는 약물을 담지한 알부민 나노입자와 상기 알부민 나노입자에 결합한 CEACAM6 항체를 포함하며, 상기 알부민 나노입자는 알부민 분자 사이 디설파이드 결합에 의해 형성되고, 상기 CEACAM6 항체는 알부민 나노입자 표면의 아민 그룹과 아마이드 결합을 하여, CEACAM6 항체가 아노이키스 내성 암세포를 타켓팅하며 암세포에 섭취된 알부민 나노입자는 세포기질에 존재하는 글루타틴온에 의해 디설파이드 결합이 끊어져 약물을 방출하는 아노이키스 내성 암세포의 화학요법을 위한 알부민 나노입자에 대한 것이다.
Also published as
Latest bibliographic data on file with the International Bureau